A noteworthy entry in S6 master_appendix sheet gp_A_FDA is for Olaparib, MOA:PARP and defective gene NF1. Combination treatment with olaparib and various inhibitors of PD-L1, VEGFR, PI3K, and AKT may effectively inhibit the growth of rapidly proliferating triple negative breast cancer cell lines [40]. This evidence concerns the gene AKT1 and triple-negative breast carcinoma.